Physician profile
Prashant Barakoti
NPI 1801011598
$16,884.96
in general payments reported to CMS, 2019-2025
58 companies · $3,377 in 2025
The $3,377 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $765 · 2021: $1,434 · 2022: $3,016 · 2023: $3,181 · 2024: $3,629 · 2025: $3,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,186.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,497.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,068.42 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $1,765.94 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $1,697.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,427.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,108.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $906.94 | 2019-2025 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $853.16 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $526.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.19 | 2019-2025 | Jardiance |
| Eisai INC. | $238.51 | 2021-2025 | |
| Amarin Pharma, INC. | $223.29 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.48 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $201.61 | 2022-2024 | |
| Corcept Therapeutics | $198.61 | 2025 | Korlym |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Barakoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.